Finder makes money from featured partners, but editorial opinions are our own. Advertiser Disclosure
C4 Therapeutics Inc is a biotechnology business based in the US. C4 Therapeutics Inc shares (CCCC) are listed on the NASDAQ and all prices are listed in US Dollars. C4 Therapeutics Inc employs 121 staff and has a trailing 12-month revenue of around 0.00.
Our top pick for
Beginners
Our top pick for
Building a portfolio
Our top pick for
Advanced traders
| Latest market close | $8.03 |
|---|---|
| 52-week range | $4.84 - $51.21 |
| 50-day moving average | $7.25 |
| 200-day moving average | $25.85 |
| Wall St. target price | $29.64 |
| PE ratio | N/A |
| Dividend yield | $0 (0%) |
| Earnings per share (TTM) | $-1.99 |
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Historical closes compared with the close of $8.03 from 2022-07-01
| 1 week (2022-06-28) | 12.31% |
|---|---|
| 1 month (2022-06-01) | N/A |
| 3 months (2022-04-05) | -63.50% |
| 6 months (2022-01-05) | -72.90% |
| 1 year (2021-07-02) | -79.78% |
|---|---|
| 2 years (2020-07-01) | N/A |
| 3 years (2019-07-01) | N/A |
| 5 years (2017-07-01) | N/A |
| Revenue TTM | $46 million |
|---|---|
| Gross profit TTM | $-41,354,000 |
| Return on assets TTM | -13.07% |
| Return on equity TTM | -30.1% |
| Profit margin | -205.47% |
| Book value | $7.48 |
| Market capitalisation | $367.9 million |
TTM: trailing 12 months
We're not expecting C4 Therapeutics Inc to pay a dividend over the next 12 months.
C4 Therapeutics, Inc. , a clinical-stage biopharmaceutical company, develops novel therapeutic candidates to degrade disease-causing proteins for the treatment of cancer, neurodegenerative conditions, and other diseases. Its lead product candidate is CFT7455, an orally bioavailable MonoDAC degrader of protein that is in Phase 1/2 trial targeting IKZF1 and IKZF3 for multiple myeloma and non-Hodgkin lymphomas, including peripheral T-cell lymphoma and mantle cell lymphoma. The company is also developing CFT8634, an orally bioavailable BiDAC degrader of BRD9, a protein target for synovial sarcoma and SMARCB1-deleted solid tumors; CFT1946, an orally bioavailable BiDAC degrader targeting V600X mutant BRAF to treat melanoma, non-small cell lung cancer (NSCLC), colorectal cancer, and other solid malignancies; CFT8919, an orally bioavailable, allosteric, and mutant-selective BiDAC degrader of epidermal growth factor receptor, or EGFR, with an L858R mutation in NSCLC; and earlier stage programs comprising RET degraders for the treatment of various cancers. C4 Therapeutics, Inc. has strategic collaborations with F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc.
Everything we know about the Citrine Global IPO, plus information on how to buy in.
Everything we know about the Genelux Corporation IPO, plus information on how to buy in.
Everything we know about the Magic Empire Global IPO, plus information on how to buy in.
Everything we know about the Intchains Group IPO, plus information on how to buy in.
Everything we know about the Biostage IPO, plus information on how to buy in.
Everything we know about the Wang & Lee Group IPO, plus information on how to buy in.
Everything we know about the OptMed IPO, plus information on how to buy in.
Everything we know about the Lichen China IPO, plus information on how to buy in.
Everything we know about the LeeWay Services IPO, plus information on how to buy in.
Everything we know about the Nano Labs IPO, plus information on how to buy in.
